First AD

Second AD

Biomarker-driven combination treatment approach in non-clear cell RCC (Met-driven) 

Video content above is prompted by the following:

Please discuss the recent data presented at ASCO 2024 on the phase 3 STELLAR trial

Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study (Abstract TPS4611)

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC  

Dr. Laurence Albiges, MD, PhD, reviews the recent findings presented at the American Society of Clinical Oncology (ASCO) 2024 meeting, specifically focusing on the results of the phase 3 STELLAR trial. 

Evolving Treatment Standards in Non-Clear Cell RCC 